KRSA (KRSA) P/E Ratio (TTM): Latest Data, Historical Trends & Peer Comparison
What is KRSA's (KRSA) P/E Ratio (TTM)?
As of Sep 17, 2026, KRSA (KRSA) P/E Ratio (TTM) is -228.96.
P/E Ratio (TTM) Historical Trend for KRSA
View KRSA's annual, quarterly, and TTM P/E Ratio (TTM) data from 2019 to 2026, including historical growth rates and trend analysis.
KRSA Historical Data
| Metric | Apr 30, 2019 | May 31, 2019 | Jun 28, 2019 | Jul 31, 2019 | Aug 30, 2019 | Sep 30, 2019 | Oct 31, 2019 | Nov 29, 2019 | Dec 31, 2019 | Jan 31, 2020 | Feb 28, 2020 | Mar 31, 2020 | Apr 30, 2020 | May 29, 2020 | Jun 30, 2020 | Jul 31, 2020 | Aug 31, 2020 | Sep 30, 2020 | Oct 30, 2020 | Nov 30, 2020 | Dec 31, 2020 | Jan 29, 2021 | Feb 26, 2021 | Mar 31, 2021 | Apr 30, 2021 | May 28, 2021 | Jun 30, 2021 | Jul 30, 2021 | Aug 31, 2021 | Sep 30, 2021 | Oct 29, 2021 | Nov 30, 2021 | Dec 31, 2021 | Jan 31, 2022 | Feb 28, 2022 | Mar 31, 2022 | Apr 29, 2022 | May 31, 2022 | Jun 30, 2022 | Jul 29, 2022 | Aug 31, 2022 | Sep 30, 2022 | Oct 31, 2022 | Nov 30, 2022 | Dec 30, 2022 | Jan 31, 2023 | Feb 28, 2023 | Mar 31, 2023 | Apr 28, 2023 | May 31, 2023 | Jun 30, 2023 | Jul 31, 2023 | Aug 31, 2023 | Sep 29, 2023 | Oct 31, 2023 | Nov 30, 2023 | Dec 29, 2023 | Jan 31, 2024 | Feb 29, 2024 | Mar 28, 2024 | Apr 30, 2024 | May 31, 2024 | Jun 28, 2024 | Jul 31, 2024 | Aug 30, 2024 | Sep 30, 2024 | Oct 31, 2024 | Nov 29, 2024 | Dec 31, 2024 | Jan 31, 2025 | Feb 28, 2025 | Mar 31, 2025 | Apr 30, 2025 | May 30, 2025 | Jun 30, 2025 | Jul 31, 2025 | Aug 29, 2025 | Sep 30, 2025 | Oct 31, 2025 | Nov 28, 2025 | Dec 31, 2025 | Jan 30, 2026 | Feb 27, 2026 | Mar 31, 2026 | Apr 30, 2026 | May 29, 2026 | Jun 30, 2026 | Jul 31, 2026 | Aug 31, 2026 | Sep 17, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E Ratio (TTM) | -3.62 | -3.00 | -2.46 | -2.00 | -2.01 | -2.56 | -0.51 | -0.40 | -0.59 | -0.71 | -0.92 | -0.60 | -0.87 | -1.04 | -1.56 | -1.22 | -2.48 | -2.22 | -0.85 | -1.24 | -1.23 | -1.27 | -1.68 | -1.22 | -1.05 | -1.56 | -2.38 | -1.86 | -2.19 | -1.97 | -1.64 | -1.57 | -1.24 | -0.95 | -0.88 | -0.93 | -0.62 | -0.53 | -0.47 | -0.81 | -0.75 | -0.77 | -0.49 | -0.87 | -0.60 | -0.61 | -0.59 | -0.43 | -0.27 | -0.25 | -0.26 | -0.27 | -0.30 | -0.29 | -0.22 | -0.49 | -0.76 | -0.69 | -0.75 | -1.65 | -1.34 | 48.56 | 41.83 | 60.45 | 2.64 | 2.18 | 2.43 | -1.13 | -1.55 | -1.89 | -1.37 | -1.45 | -2.00 | -3.06 | -3.04 | -2.77 | -4.24 | -4.37 | -3.55 | -2.82 | -2.21 | -2.36 | -2.35 | -1.86 | -3.98 | -2.59 | -2.78 | -3.05 | -2.58 | -228.96 |
KRSA (KRSA) : Definition & Explanation
PE Ratio is a valuation multiple that compares the market's price for the company with a financial output such as earnings, sales, book value, cash flow, or EBITDA.
It matters because pe ratio gives investors a quick way to compare how aggressively or conservatively a stock is being priced relative to the business underneath it.
It is a calculated measure rather than a directly reported financial statement line. The market value side usually comes from share price, market cap, or enterprise value, and the denominator usually comes from the company's reported financials.
Investors rarely treat pe ratio as a standalone answer. It is more useful when paired with growth, margins, balance sheet risk, and cash generation, since a low multiple can reflect either opportunity or weaker business quality.
KRSA (KRSA) P/E Ratio (TTM) vs Competitors | Chemical Pharmaceuticals Comparison
Compare KRSA's (KRSA) P/E Ratio (TTM) with competitors. View latest market cap and P/E Ratio (TTM) performance.
| Ticker | Company | Market Cap | P/E Ratio (TTM) |
|---|---|---|---|
| LLY | Eli Lilly | 1.08T | 40.61 |
| JNJ | Johnson & Johnson | 651.20B | 30.96 |
| ABBV | Abbvie | 466.55B | 73.94 |
| NVS | Novartis | 267.85B | 21.00 |
| NVO | Novo Nordisk | 190.81B | 10.62 |
| BMY | Bristol-Myers Squibb | 128.36B | 13.83 |
| SNY | Sanofi | 104.75B | 22.96 |
| GSK | GSK | 103.28B | 16.25 |
| TAK | Takeda Pharmaceutical | 60.21B | -230.29 |
| TEVA | Teva Pharmaceutical | 45.71B | -81.18 |
| ONC | Beone Medicines | 40.19B | 61.29 |
| RPRX | Royalty Pharma | 33.88B | 41.73 |
| VTRS | Viatris | 19.68B | -47.91 |
| JAZZ | Jazz Pharmaceuticals | 15.83B | 16.83 |
| NBIX | Neurocrine Biosciences | 15.43B | 21.88 |
| EXEL | Exelixis | 14.49B | 16.84 |
| CORT | Corcept Therapeutics | 12.42B | 228.79 |
| MDGL | Madrigal | 12.35B | -37.98 |
| AXSM | Axsome Therapeutics | 11.22B | -58.57 |
| RDY | Dr. Reddy'S Laboratories | 10.17B | 30.09 |
| ALKS | Alkermes | 7.84B | 118.51 |
| BLTE | Belite Bio | 6.86B | -67.02 |
| RYTM | Rhythm | 6.82B | -32.43 |
| MIRM | Mirum | 6.42B | -7.46 |
| BLCO | Bausch + Lomb | 5.99B | -35.03 |
| AMRX | Amneal | 5.84B | 37.10 |
| LGND | Ligand | 5.68B | 28.78 |
| DFTX | Definium | 5.20B | -14.69 |
| AMLX | Amylyx | 4.26B | -28.01 |
| TLX | Telix | 4.25B | -596.35 |
KRSA (KRSA) P/E Ratio (TTM) Related Metrics
Explore key financial metrics related to KRSA's (KRSA) P/E Ratio (TTM). Click on the links below to dive deeper into similar and complementary indicators.
About KRSA (KRSA)
KRSA
Industry
--
Established Date
--
Listing Date
--
Exchange
--
Full-time Employees
--
Fiscal Year Ends
--
Website
--
Security Type
--
Office address
--
Business
--
Introduction
--